HASH:CA:TSV-Simply Solventless Concentrates Ltd. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.73

Change

-0.02 (-2.67)%

Market Cap

USD 0.07B

Volume

0.23M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.08 (+0.72%)

USD 0.14B
SBBC:CA Simply Better Brands Corp

+0.03 (+2.97%)

USD 0.10B
ZYUS:CA ZYUS Life Sciences Corporation

-0.05 (-5.56%)

USD 0.06B
LOVE:CA Cannara Biotech Inc

+0.01 (+1.32%)

USD 0.06B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.04B
LSL:CA LSL Pharma Group Inc.

-0.02 (-3.61%)

USD 0.04B
ROMJ:CA Rubicon Organics Inc

N/A

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.01B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 0.01B

ETFs Containing HASH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.41% 27% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.41% 27% F 15% F
Trailing 12 Months  
Capital Gain 630.00% 94% A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 630.00% 94% A 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.63% 79% B- 67% D+
Dividend Return 17.63% 79% B- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.69% 32% F 33% F
Risk Adjusted Return 19.87% 74% C 69% C-
Market Capitalization 0.07B 89% A- 87% B+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.